{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:01:39Z","timestamp":1791849699213,"version":"4.3.4"},"reference-count":50,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Zygomycosis, an infection that is associated with significant morbidity and mortality, is becoming common in immunocompromised patients. Posaconazole is a new extended-spectrum azole antifungal that has demonstrated in vitro and in vivo activity against zygomycetes. This report provides the results from the first 24 patients with active zygomycosis who were enrolled in two open-label, nonrandomized, multicentered compassionate trials that evaluated oral posaconazole as salvage therapy for invasive fungal infections. Posaconazole was usually given as an oral suspension of 200 mg four times a day or 400 mg twice a day. Eleven (46%) of the infections were rhinocerebral. Duration of posaconazole therapy ranged from 8 to 1,004 days (mean, 292 days; median, 182 days). Rates of successful treatment (complete cure and partial response) were 79% in 19 subjects with zygomycosis refractory to standard therapy and 80% in 5 subjects with intolerance to standard therapy. Overall, 19 of 24 subjects (79%) survived infection. Survival was also associated with surgical resection of affected tissue and stabilization or improvement of the subjects' underlying illnesses. Failures either had worsening of underlying illnesses or requested all therapy withdrawn; none of the failures received more than 31 days of posaconazole. Posaconazole oral solution was well tolerated and was discontinued in only one subject due to a drug rash. Posaconazole appears promising as an oral therapy for zygomycosis in patients who receive required surgery and control their underlying illness.<\/jats:p>","DOI":"10.1128\/aac.50.1.126-133.2006","type":"journal-article","created":{"date-parts":[[2005,12,23]],"date-time":"2005-12-23T05:07:51Z","timestamp":1135314471000},"page":"126-133","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":468,"title":["Posaconazole as Salvage Therapy for Zygomycosis"],"prefix":"10.1128","volume":"50","author":[{"given":"R. N.","family":"Greenberg","sequence":"first","affiliation":[{"name":"Medicine Service, Department of Veterans Affairs Medical Center, Lexington, Kentucky"},{"name":"University of Kentucky, Department of Medicine, Lexington, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mullane","sequence":"additional","affiliation":[{"name":"University of Chicago Medical School, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-A. H.","family":"van Burik","sequence":"additional","affiliation":[{"name":"University of Minnesota School of Medicine, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Raad","sequence":"additional","affiliation":[{"name":"M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Abzug","sequence":"additional","affiliation":[{"name":"University of Colorado and Children's Hospital, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Anstead","sequence":"additional","affiliation":[{"name":"Department of Medicine, South Texas Veterans Healthcare System, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Herbrecht","sequence":"additional","affiliation":[{"name":"Hopital de Hautepierre, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Langston","sequence":"additional","affiliation":[{"name":"Emory University Hospital, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. A.","family":"Marr","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Schiller","sequence":"additional","affiliation":[{"name":"University of California at Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Wingard","sequence":"additional","affiliation":[{"name":"University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. E.","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Georgetown University Hospital Lombardi Cancer Center, Washington, D.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. G.","family":"Revankar","sequence":"additional","affiliation":[{"name":"Dallas VA Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Corcoran","sequence":"additional","affiliation":[{"name":"Amgen, Inc., Regulatory Affairs, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Kryscio","sequence":"additional","affiliation":[{"name":"University of Kentucky, Department of Statistics and Public Health, Lexington, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hare","sequence":"additional","affiliation":[{"name":"Schering-Plough Research Institute, Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.8.2656-2662.1999"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/323335"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80125-X"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2001.0831"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.804-808.2004"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3647-3650.2003"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg020"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2004.00959.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.5858\/2001-125-0375-HFOZ"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/320524"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/517193"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(02)00037-5"},{"key":"e_1_3_2_14_2","unstructured":"Graybill J. R. I. Raad R. Negroni G. Corcoran and L. Pedicone. 2004. Posaconazole (POS) long-term safety in patients with invasive fungal infections (IFIs) abstr. M-1025 p. 415. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_15_2","first-page":"460","volume":"20","year":"2001","unstructured":"Herbrecht, R., V. Letscher-Bru, R. A. Bowden, S. Kusne, E. J. Anaissie, J. R. Graybill, G. A. Noskin, B. A. Oppenheim, E. Andr\u00e8s, and L. A. Pietrelli. 2001. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur. J. Clin. Microbiol. Infect. Dis.20:460-466.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2002.0972"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/375822"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/423274"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/1024533031000090810"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80126-1"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01170.x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912163412507"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/428780"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/313803"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.12.1301"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701885"},{"key":"e_1_3_2_27_2","unstructured":"Mann P. A. R. Patel G. Chen and P. M. McNicholas. 2004. Posaconazole is a potent inhibitor of sterol 14\u03b1-demethylation in zygomycetes abstr. M-1978 p. 442. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/339202"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200402263500923"},{"key":"e_1_3_2_30_2","first-page":"1068","volume":"85","year":"2000","unstructured":"Nosari, A., P. Oreste, M. Montillo, G. Carrafiello, M. Draisci, G. Muti, A. Molteni, and E. Morra. 2000. Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica85:1068-1071.","journal-title":"Haematologica"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2002000700005"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3983214.x"},{"key":"e_1_3_2_33_2","unstructured":"Perfect J. R. D. R. Graham G. Corcoran L. Pedicone and I. Raad. 2004. Posaconazole (POS) safety and efficacy in elderly (\u226565 years of age) patients with invasive fungal infections (IFIs) abstr. 630 p. 164. Abstr. 42nd Annu. Meet. Infect. Dis. Soc. Am. Infectious Diseases Society of America Alexandria Va."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/374557"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1032-1037.2002"},{"key":"e_1_3_2_36_2","unstructured":"Raad I. S. Chapman R. Bradsher V. Morrison M. Goldman J. Graybill J. R. Perfect T. Patterson T. Walsh G. Corcoran and P. Pappas. 2004. Posaconazole (POS) salvage therapy for invasive fungal infections (IFI) abstr. M-669 p. 412. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.2.236"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/318144"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/432579"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2000.0739"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704552"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1054\/jocn.2000.0818"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1086\/422723"},{"key":"e_1_3_2_44_2","unstructured":"Skiest D. D. Ward A. Northland J. Reynes and W. Greaves. 1999. Treatment of azole-refractory candidiasis in HIV disease abstr. 1162 p. 491. Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004630-199907000-00005"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1581-1582.2002"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.7.2310-2312.2002"},{"key":"e_1_3_2_48_2","unstructured":"Vazquez J. A. R. Northland S. Miller G. Dickinson and G. Wright. 2000. Posaconazole compared to fluconazole for oral candidiasis in HIV-positive patients abstr. 1107 p. 372. Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-002-0781-6"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1470-9465.2004.00839.x"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1086\/516353"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.50.1.126-133.2006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.50.1.126-133.2006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T14:05:49Z","timestamp":1645452349000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.50.1.126-133.2006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["10.1128\/AAC.50.1.126-133.2006"],"URL":"https:\/\/doi.org\/10.1128\/aac.50.1.126-133.2006","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.8357.465851","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"2005-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-10-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}